Compare ATOS & CLIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATOS | CLIR |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.2M | 33.3M |
| IPO Year | 2010 | 2011 |
| Metric | ATOS | CLIR |
|---|---|---|
| Price | $5.43 | $4.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $23.00 | $20.00 |
| AVG Volume (30 Days) | 53.0K | ★ 63.5K |
| Earning Date | 05-12-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,758.00 | ★ $530,000.00 |
| Revenue This Year | N/A | $34.29 |
| Revenue Next Year | N/A | $67.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.53 | $0.39 |
| 52 Week High | $7.56 | $7.56 |
| Indicator | ATOS | CLIR |
|---|---|---|
| Relative Strength Index (RSI) | 53.31 | 56.93 |
| Support Level | $0.66 | $0.58 |
| Resistance Level | $5.56 | $7.56 |
| Average True Range (ATR) | 0.34 | 0.58 |
| MACD | -0.02 | -0.21 |
| Stochastic Oscillator | 50.32 | 22.92 |
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
ClearSign Technologies Corp is engaged in designing and develop technologies for the purpose of decarbonization and improving key performance characteristics of industrial and commercial combustion systems, including emission and operational performance, energy efficiency and overall cost-effectiveness. Its ClearSign Core technology has been proved to be in full scale industrial test furnaces and boilers and first customer installations are currently operating in normal commercial applications The company offers products that include process burners, boiler burners, flares, and ClearSign Eye. The company operates in one segment: Combustion segment. The products of the company include: Process Burners, Midstream and Power, Flares, Boiler Burners, and Sensing Technology.